Introduction
============

In the United States, the incidence of gastric cancer is not particularly high compared with that observed in other countries; however, \~21,600 patients were diagnosed with gastric cancer in 2013, and the 5-year survival rate for all stages of the disease was only 27% ([@b1-ol-0-0-6257]). The disease is also a leading cause of cancer-associated mortality in males and females in Japan ([@b2-ol-0-0-6257]). The prognosis for patients with gastric cancer has gradually improved over the last 10 years; however, the 5-year survival rate of metastasized gastric cancer remains at \~40% ([@b3-ol-0-0-6257]). Therefore, the identification and development of therapeutics is required to improve the prognosis of patients with advanced gastric cancer.

Integrin associated protein (CD47) is a glycoprotein that is ubiquitously expressed on the plasma membrane of all hematopoietic cells and the majority of other cell types ([@b4-ol-0-0-6257],[@b5-ol-0-0-6257]). Oldenborg *et al* ([@b6-ol-0-0-6257]) revealed that CD47 is a marker of self on murine red blood cells (RBCs), and that CD47-negative RBCs are rapidly eliminated from the circulation by macrophage phagocytosis. Furthermore, tumor cells expressing CD47 evade elimination by macrophages ([@b7-ol-0-0-6257]). The clinical significance of CD47 expression in blood cancer has been extensively studied ([@b6-ol-0-0-6257]--[@b8-ol-0-0-6257]). In solid tumors, including bladder cancer, cells expressing CD47 were identified to be of a tumor-initiating cell population ([@b9-ol-0-0-6257]). In addition, the prognosis of patients with breast cancer with high levels of CD47 expression was significantly poorer compared with patients with low expression of CD47 ([@b10-ol-0-0-6257]). In 2015, it was revealed that in addition to being associated with macrophage phagocytosis, a CD47 blockade drives the T-cell mediated elimination of immunogenic tumors ([@b11-ol-0-0-6257]). Therefore, CD47 is emerging as a focus of the field of immunotherapy.

Targeting CD47 via anti-CD47 antibody therapy was recently proposed ([@b12-ol-0-0-6257]). A variety of cancer types may be targeted with this therapy, and therefore, the status of CD47 expression requires investigation in various malignant tumors. However, little is known about the status of CD47 expression in patients with gastric cancer. Thus, the present study aimed to determine the level of CD47 expression in the primary tumor, peripheral blood (PB) and bone marrow (BM) of patients with gastric cancer, and to explore the potential of anti-CD47 antibody therapy in gastric cancer.

Materials and methods
=====================

### Patients

A total of 168 patients (108 male, 60 female; mean age, 69±11.8 years) who were diagnosed with gastric cancer and treated with gastrectomy, including lymphadenectomy, at Kyushu University Beppu Hospital (Oita, Japan) between April 2000 and April 2005 were enrolled in the present study. Written informed consent was obtained from all patients according to the guidelines provided by the Institutional Research Board of Kyushu University Beppu Hospital, which approved the present study. None of the patients received pre-surgical chemotherapy or radiotherapy. Pathological diagnosis and disease staging were performed according to the criteria of the Japanese Classification of Gastric Carcinoma ([@b13-ol-0-0-6257]). All patients were monitored closely for the recurrence of cancer following surgery every 3 months for 3--5 years.

### Sample collection

PB samples were obtained from 6 healthy volunteers and the 168 patients with gastric cancer prior to surgery. PB samples (10 ml) were taken and mixed with 4 ml ISOGEN-LS reagent (Nippon Gene Co., Ltd., Toyama, Japan) per 1 ml whole blood. The sample was stored for 5 min at room temperature, then snap-frozen immediately in liquid nitrogen and stored at −80°C until required for RNA extraction.

BM samples were obtained from 160 patients with gastric cancer under general anesthesia prior to surgery. BM samples were taken from the sternum using a 15-gauge needle. Since there was a possibility of aspirating skin with the BM samples, the first 1 ml of the sample was discarded, and another syringe was used to aspirate 20--30 ml of BM. ISOGEN-LS reagent was then added as previous, and the BM samples were subsequently processed in the same manner as the PB samples.

A total of 10 tumor and corresponding normal 4-µm thick formalin-fixed paraffin-embedded tissue section samples from the patients who underwent surgery were also obtained and used for immunohistochemical analysis. A total of 6 autopsy bone marrow samples were collected, 3 from patients who succumbed to advanced gastric cancer, and 3 from pneumonia. Formalin-fixed paraffin-embedded 4-µm tissue sections were made from these bone marrow samples.

### RNA preparation and reverse transcription (RT)

Total RNA was extracted from PB and BM samples using the ISOGEN-directed chloroform extraction and isopropanol precipitation protocol, as described previously ([@b14-ol-0-0-6257]). cDNA was synthesized using RT as described previously ([@b15-ol-0-0-6257]).

### Cell lines

The human gastric cancer cell lines KATO-III, MKN-1, MKN-45 and MKN-74 were provided by the Cell Resource Center for Biomedical Research (Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan). The NUGC-4 (JCRBO834) cell line was provided by the Japanese Collection of Research Bioresources Cell Bank (National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan). KATO-III cells were maintained in McCoy5A medium supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin antibiotics (all from Thermo Fisher Scientific, Inc., Waltham, MA, USA). The other cell lines were maintained in an RPMI-1640 medium supplemented with 10% fetal calf serum and 1% penicillin and streptomycin (all from Thermo Fisher Scientific, Inc.). All cell lines were cultured in 10 cm culture dishes with 5% CO~2~ at 37°C. Cultured cells from each cell line were dissolved in 350 µl of Buffer RLT containing 1% β-mercaptoethanol, and total RNA was extracted and purified using the RNeasy Mini kit (Qiagen GmbH, Hilden, Germany) in accordance with the manufacturer\'s protocol.

### Quantitative polymerase chain reaction (qPCR) evaluation of CD47 expression in clinical samples

The following primers were used to amplify CD47 from the RNA samples from the cells, PB and BM: Sense, 5′-GGCAATGACGAAGGAGGTTA-3′ and antisense, 5′-ATCCGGTGGTATGGATGAGA-3′. GAPDH, used as an internal control, was amplified using the following primers: Sense, 5′-TGAACGGGAAGCTCACTGG-3′ and antisense, 5′-TCCACCACCCTGTTGCTGTA-3′. qPCR was performed using the LightCycler^™^ system and SYBR-Green I dye (both from Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer\'s protocol. Briefly, each reaction contained 80 ng cDNA, 2 µl DNA Master SYBR-Green I mix, 50 ng primers and 2.4 µl 25 mM MgCl~2~. The final volume was adjusted to 20 µl with water. qPCR was performed with the following thermocycling conditions: Initial denaturation at 95°C for 10 min; followed by 40 cycles of 95°C for 10 sec; annealing at 60°C for 10 sec; and extension at 72°C for 10 sec. The product was confirmed by gel electrophoresis. Following amplification, the products were subjected to a temperature gradient from 68--95°C at a rate of 0.2°C/sec, under continuous fluorescence monitoring, in order to produce a melt curve for each product. All concentrations were calculated relative to the concentration of the positive control, cDNA produced from Human Universal Reference Total RNA (Clontech Laboratories, Inc., Mountain View, CA, USA), using a previously described method ([@b16-ol-0-0-6257]). The negative control was water. Normalized expression values were obtained by dividing the mRNA concentration of CD47 by that of the internal control.

### Immunohistochemistry

Formalin-fixed and paraffin-embedded tissue sections corresponding to the samples used for mRNA expression analysis were analyzed. Tissue sections were de-paraffinized, soaked in 0.01 M sodium citrate buffer and boiled in a microwave oven for 15 min at 500 W to retrieve cell antigens. In the case of bone marrow samples, decalcification was performed according to the manufacturer\'s protocol (Super Decalcifier I; Polyscience Inc., Warminster, PA, USA). The tissue sections were stained immunohistochemically using the streptavidin-biotin peroxidase method (Universal Dako Cytomation LSAB^®^ kit; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) according to the manufacturer\'s protocol, with primary antibodies against CD47 (mouse monoclonal antibody; dilution, 1:200; cat. no. sc-12730; Santa Cruz Biotechnology, Inc., Dallas, TX, USA). Briefly, the tissue sections were blocked with 3% H~2~O~2~ for 5 min and incubated overnight with the primary antibody at 4°C. The samples were then washed with TBS buffer and subsequently incubated with the secondary antibody from the LSAB^®^ kit for 30 min at room temperature.

### Cell sorting

Immunomagnetic cell sorting was performed on 30 ml of PB collected from 6 healthy donors and 30 ml BM collected from 6 patients with gastric cancer. Fractionation was performed using the autoMACS^®^ Pro Separator (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the manufacturer\'s protocol. Cells were prepared as follows: The PB or BM sample was loaded into 10 ml of Ficoll density medium (GE Healthcare Life Sciences, Chalfont, UK) prepared in a 50 ml polypropylene tube. Gradient centrifugation was subsequently performed at room temperature for 30 min at 450 × g. Sample interfaces were collected subsequent to discarding the supernatants. The interface containing the mononuclear fractionated cells was washed twice with 20 ml PBS and centrifuged at 150 × g for 5 min at 4°C.

Human CD326 \[epithelial cell adhesion molecule (EpCAM)\]-phycoerythrin MicroBeads (Miltenyi Biotec GmbH) were used for positive selection of viable epithelial tumor cells from the samples, CD45-MicroBeads (Miltenyi Biotec GmbH) were used to detect leukocytes and CD14-MicroBeads (Miltenyi Biotec GmbH) were applied for the detection of monocytes and macrophages. The MicroBeads were used according to the manufacturer\'s protocol. In brief, the CD14+ fraction was sorted, then the CD14-/CD45+ fraction and finally the EpCAM-positive fraction ([Fig. 1A](#f1-ol-0-0-6257){ref-type="fig"}). The expression of CD47 in each fraction was measured using RT-qPCR as described above.

### Statistical analysis

The association between CD47 mRNA expression and clinicopathological factors was evaluated using the χ^2^ test. For the evaluation of primary tumor tissue samples, the median CD47 mRNA expression value was used as the cut-off to divided patients into high CD47 expression and low CD47 expression groups. For PB and BM samples, the median value was calculated using all samples. Overall survival was calculated by the Kaplan-Meier method and the differences in survival between the groups were compared using the log-rank test. All tests were performed using JMP software version 12.2.0 (SAS Institute, Inc., Cary, NC, USA) and GraphPad Prism software version 6.0 h (GraphPad Software, Inc., La Jolla, CA, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Expression of CD47 in primary gastric tumors

Immunohis-tochemical analysis was performed to investigate the protein expression level of CD47 in the tissues of gastric cancer and adjacent normal mucosa. In normal gastric mucosa, intracellular expression of CD47 protein was observed in the bottom layer of the gastric gland, which almost disappeared in the upper layer ([Fig. 2A](#f2-ol-0-0-6257){ref-type="fig"}). In gastric tumor tissues, a varying pattern of CD47 protein expression was observed. In one case, CD47 was highly expressed throughout the tissue, and this case was diagnosed as well-differentiated adenocarcinoma ([Fig. 2B](#f2-ol-0-0-6257){ref-type="fig"}, case 1). In another case, the expression of CD47 was relatively high, and the expression pattern was not consistent throughout the tissue; this case was diagnosed as moderately-differentiated adenocarcinoma ([Fig. 2B](#f2-ol-0-0-6257){ref-type="fig"}, case 2). The expression of CD47 nearly disappeared in another case, which was diagnosed as poorly-differentiated adenocarcinoma ([Fig. 2B](#f2-ol-0-0-6257){ref-type="fig"}, case 3).

As demonstrated by immunohistochemical staining, CD47 protein levels appeared to be associated with the histological grade, and therefore, the CD47 mRNA expression level was compared with the histological grade; however, no significant difference was observed between CD47 expression and different histological grades (data not shown). The expression of CD47 was compared between gastric tumor tissue and corresponding normal tissue using RT-qPCR. However, as demonstrated in [Fig. 2C](#f2-ol-0-0-6257){ref-type="fig"}, no significant difference was observed in CD47 mRNA expression between primary tumor tissue and normal tissue.

To determine the association between CD47 mRNA expression and the clinicopathological characteristics of patients with gastric cancer, patients were divided into two groups: High CD47 expression and low CD47 expression, however, no significant association was observed between CD47 expression and any of the clinicopathological factors tested ([Table I](#tI-ol-0-0-6257){ref-type="table"}). In addition, the overall survival rate between the high and low CD47 expression groups was compared, and no significant difference was observed between the two groups ([Fig. 2D](#f2-ol-0-0-6257){ref-type="fig"}).

### Expression of CD47 in the PB

CD47 expression in PB was analyzed, and its association with the clinicopathological characteristics of patients with gastric cancer was investigated ([Table II](#tII-ol-0-0-6257){ref-type="table"}). Tumor size and depth were significantly increased in patients with low compared with high CD47 expression. The frequency of lymphatic invasion was also significantly higher in the low compared with high CD47 expression group. The percentage of tumor type 2--5 was significantly higher at 73% in the CD47 low expression group compared with 44% in the CD47 high expression group. The frequency of lymph node metastasis and lymphatic invasion in the low CD47 expression group was significantly increased compared with that in the high CD47 expression group. As a result, the clinical tumor stage of the low CD47 expression group was significantly increased compared with that of the high CD47 expression group. The expression level of CD47 mRNA was compared with the clinical tumor stage in the PB sample ([Fig. 3A](#f3-ol-0-0-6257){ref-type="fig"}). CD47 expression was demonstrated to be highest in tumor stage I in PB samples ([Fig. 3A](#f3-ol-0-0-6257){ref-type="fig"}).

### Expression of CD47 in the BM

CD47 protein expression in BM samples was analyzed using immunohistochemical staining. As demonstrated in [Fig. 4](#f4-ol-0-0-6257){ref-type="fig"}, CD47 expression was markedly increased in the BM of patients with stage IV gastric cancer. To assess the importance of CD47 expression in the BM, the clinicopathological characteristics of patients with gastric cancer who exhibited high or low CD47 mRNA expression were compared. As indicated in [Table III](#tIII-ol-0-0-6257){ref-type="table"}, the percentages of lymphatic invasion and lymph node metastasis were significantly higher in the high CD47 expression group compared with the low CD47 expression group. By contrast, the frequency of distant metastasis was significantly higher in the low CD47 expression group compared with the high CD47 expression group. In addition, the clinical tumor stage was significantly increased in the high compared low CD47 expression group. The BM expression of CD47 mRNA was significantly higher in stage III/IV patients than in stage I/II patients ([Fig. 3B](#f3-ol-0-0-6257){ref-type="fig"}).

### Origin of CD47 in the PB and BM

The results of the analysis of the association between CD47 mRNA expression and the clinicopathological characteristics of patients with gastric cancer were different in primary tumors, PB and BM. To detect the original source of CD47 expression in PB and BM, cell sorting was performed. PB and BM samples were sorted into the following four fractions ([Fig. 1A](#f1-ol-0-0-6257){ref-type="fig"}): Fraction 1, whole blood cells; fraction 2 \[myeloid cell-specific leucine-rich glycoprotein (CD14)^+^ cells\], macrophages or monocytes; fraction 3 (CD14^−^/CD45^+^ cells), lymphocytes; and fraction 4 (CD14^−^/CD45^−^/EpCAM^+^ cells), circulating tumor cells. Prior to the analysis, CD47 expression was confirmed in 4 gastric cancer cell lines by RT-qPCR (data not shown). The expression of CD47 mRNA in each fraction is demonstrated in [Fig. 1B and C](#f1-ol-0-0-6257){ref-type="fig"}. CD47 mRNA expression was expected to be highest in the circulating tumor cell fraction; however, the fraction expressing CD47 mRNA was larger in the PB ([Fig. 1B](#f1-ol-0-0-6257){ref-type="fig"}) and BM ([Fig. 1C](#f1-ol-0-0-6257){ref-type="fig"}) samples than the lymphocyte fraction.

Discussion
==========

In the present study, the localization of CD47 protein was confirmed in normal tissue and primary gastric tumor tissue using immunohistochemical staining. Despite initial expectations, no statistically significant association was observed between primary tumor CD47 expression and clinicopathological factors, which has previously been detected in hematological malignancies ([@b7-ol-0-0-6257],[@b17-ol-0-0-6257],[@b18-ol-0-0-6257]) and breast cancer ([@b10-ol-0-0-6257]). The Kaplan-Meier overall survival curve revealed that the survival rate of the high CD47 expression group was decreased compared with the low CD47 expression group from 3 years following surgery. This indicates that high CD47 expression is associated with late phase metastasis or recurrence of gastric cancer; however, the difference in survival between the two groups did not reach a statistically significant level. By contrast, low expression of CD47 in PB samples was significantly associated with increased tumor depth, lymphatic invasion, lymph node metastasis and clinical tumor stage. Conversely, high expression of CD47 in BM samples was associated with increased tumor depth, lymphatic invasion, lymph node metastasis and clinical stage. It was also revealed that CD47 mRNA expression was highest in the lymphocyte fraction in PB and BM samples. The contradiction of the CD47 expression pattern between the primary tumor, PB and BM must be explained.

In normal gastric tissue, CD47 expression was limited to the lower layer, termed the fundic glands, in the current study. The expression of CD47 is particularly observed from the portion of isthmus to the base of the glands. The fundic glands contain gastric mucosal stem cells and progenitor cells ([@b19-ol-0-0-6257]--[@b21-ol-0-0-6257]). By expressing CD47, the stem cells evade macrophage phagocytosis and elimination ([@b6-ol-0-0-6257]), and therefore the CD47 expression observed in normal mucosa is consistent with previous reports.

In primary gastric tumors, there was no indication of any statistical association between CD47 mRNA expression and clinicopathological factors. In the immunohistochemical staining analysis, a varied pattern of staining was observed, but there was no definitive pattern indicating that CD47 protein expression contributes to macrophage phagocytosis evasion. In addition, it was difficult to objectively evaluate which staining patterns were CD47-dominant or -negative; thus, it may not be appropriate to evaluate CD47 expression using immunohistochemical staining analysis in cancer. To make objective evaluations, the mRNA expression level of CD47 was calculated; however, bulky samples were used for mRNA collection in the present study, such that the heterogeneity of the tumor as a whole may have been erased.

In PB, upregulation of CD47 mRNA expression was associated with improved clinicopathological factors and early stage disease. By contrast, the association between CD47 expression and clinicopathological factors was the opposite in the BM. CD47 mRNA was expressed in the lymphocyte fraction in PB and BM samples, and this expression was low in the circulating tumor cell fraction, indicating that CD47 mRNA expression reflects lymphocytes but not cancer cells. Downregulation of CD47 is presumed to be caused by a reduction in lymphocytes. Several studies have indicated that the neutrophil:lymphocyte ratio (NLR) is a prognostic marker for gastric cancer ([@b22-ol-0-0-6257]--[@b27-ol-0-0-6257]). In early gastric cancer, cancer-associated mortality has been reported to be significantly more frequent among patients with an elevated NLR (\>2) ([@b28-ol-0-0-6257]). In advanced gastric cancer, upregulation of the NLR to \>2.5 is associated with a poor prognosis ([@b29-ol-0-0-6257]). The cause of the elevated NLR in this study was due to a surge in neutrophils and decline in lymphocytes, which is consistent with the decline in CD47 expression observed in the present study.

Lymphocyte reduction may be explained partially by the effect of an elevated release of several biological factors and cytokines into the PB from cancer tissues. Saito *et al* ([@b30-ol-0-0-6257]) demonstrated that a decline in natural killer (NK) cells, a type of lymphocyte, was caused by elevated tumor necrosis factor ligand superfamily member 6 expression, which shortened the lifespan of circulating NK cells by inducing their apoptosis. By contrast, the elevation of lymphocytes in BM is potentially the result of reactive proliferation in response to decreased lymphocytes in the PB ([Fig. 5](#f5-ol-0-0-6257){ref-type="fig"}).

The reason for the discrepancy between the findings for CD47 expression in gastric cancer compared with blood and breast cancer requires further analysis. In the present study, the level of CD47 expression was investigated using PB samples, so that the expression level of CD47 would be representative of all cells in the blood, including lymphocyte and RBCs expressing CD47. Future studies should also collect the circulating tumor cells for analysis of CD47 expression levels.

Recently, Yoshida *et al* ([@b31-ol-0-0-6257]) reported that the survival rate of patients with CD47-expressing gastric cancer was significantly worse compared with that of patients with CD47-negative gastric cancer, using immunohistochemical staining analysis. In the present study, increased CD47 mRNA expression in the primary gastric tumor was not an adverse prognostic factor. This suggests that there may be post-transcriptional differences that cause CD47 protein expression to be higher, such as disruption of the protein degradation or transportation.

To the best of our knowledge, this is the first study to analyze CD47 expression in primary tumors, PB and BM simultaneously in patients with gastric cancer. The results indicate that CD47 expression in the PB and BM may serve as a marker to analyze the immunological function of patients with gastric cancer; however, to elucidate the significance of CD47 in gastric cancer is a complicated task. Therefore, if anti-CD47 antibody treatment is considered for gastric cancer, it may not be appropriate to make the decision based on the measurement of CD47 for this disease.
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![Schema of cell sorting and CD47 expression in peripheral blood and bone marrow. (A) Schema of the cell sorting procedure. (B) Comparison of CD47 mRNA expression in each fraction of peripheral blood. (C) Comparison of CD47 mRNA expression in each fraction of bone marrow. CD47, integrin-associated protein; CD14, myeloid cell-specific leucine-rich glycoprotein; CD45, protein tyrosine phosphatase receptor type C; EpCAM, epithelial cell adhesion molecule.](ol-14-01-0801-g00){#f1-ol-0-0-6257}

![CD47 expression in primary tumor and normal mucosa tissues. (A) Immunohistochemical CD47 staining of normal mucosa of the stomach. Left panels, ×10 magnification; right panels, ×40 magnification. The right upper figure is the upper layer, and the right lower figure, the lower layer of the mucosa. (B) Immunohistochemical CD47 staining of gastric cancer tissues. Case 1 is well-differentiated adenocarcinoma, case 2 is moderately-differentiated adenocarcinoma and case 3 is poorly-differentiated adenocarcinoma. (C) Comparison of CD47 mRNA expression between primary gastric tumor tissue and normal gastric tissue. (D) Overall survival curves of the high and low CD47 expression groups. CD47, integrin-associated protein.](ol-14-01-0801-g01){#f2-ol-0-0-6257}

![Association between CD47 mRNA expression in the (A) peripheral blood or (B) bone marrow and the tumor clinical stage. \*P\<0.05. CD47, integrin-associated protein.](ol-14-01-0801-g02){#f3-ol-0-0-6257}

![H&E and immunohistochemical staining for CD47 in the bone marrow collected from a patient without cancer and a patient with stage IV gastric cancer. The left panels are H&E stained; right panels are immunohistochemically stained for CD47. Upper panels, ×20 magnification; lower panels, ×40 magnification. H&E, hematoxylin & eosin; CD47, integrin-associated protein.](ol-14-01-0801-g03){#f4-ol-0-0-6257}

![Hypothetical schema explaining the results of the present study. CD47, integrin-associated protein; IL10, interleukin-10; FasL, tumor necrosis factor ligand superfamily member 6; TGFβ, transforming growth factor β; TNFα, tumor necrosis factor α.](ol-14-01-0801-g04){#f5-ol-0-0-6257}

###### 

Association between CD47 mRNA expression in tumor tissue and the clinicopathological characteristics of patients with gastric cancer.

                                                     CD47 expression group                   
  -------------------------------------------------- ----------------------- --------------- -----------------------------------------------------
  Total, n                                           65                      68              --
    Age, years, mean ± SD                            64.74±1.37              68.47±1.34      0.0528
    Age distribution, n ≥70/\<70 years (% ≥70)       27/38 (41.6)            29/39 (42.6)    0.897
    Gender, male/female (% male)                     42/23 (64.6)            42/26 (61.7)    0.733
  Tumor factors                                                                              
    Tumor size, mm, mean ± SD                        49.85±26.03             53.79±34.19     0.458
    Tumor size distribution, n ≥50/\<50 mm (% ≥50)   31/34 (47.6)            39/29 (57.3)    0.0497^[a](#tfn1-ol-0-0-6257){ref-type="table-fn"}^
    Depth of tumor, n T1-2/T3-4 (% T1-2)             43/22 (66.2)            46/22 (67.7)    0.855
    Tumor type, n type 0--1/2-5 (% 0--1)             13/52 (20.0)            21/47 (30.9)    0.149
    Lymphatic invasion, n +/− (% +)                  43/22 (61.2)            42/26 (61.8)    0.598
    Vascular invasion, n +/− (% +)                   19/46 (29.2)            14/54 (20.6)    0.248
  Metastatic factors                                                                         
    Lymph node metastasis, n +/− (% +)               41/24 (63.1)            44/24 (64.7)    0.845
    Liver metastasis, n +/− (% +)                    2/63 (3.1)              6/62 (8.8)      0.154
    Peritoneal (micro) metastasis, n +/− (% +)         9/56 (13.9)             9/59 (13.2)   0.918
    Peritoneal (macro) metastasis, n +/− (% +)         9/56 (13.9)             9/59 (13.2)   0.918
    Distant metastasis, n +/− (% +)                  1/64 (1.5)              4/64 (5.9)      0.173
  Clinical stage, n I/II--IV (% I)                   21/44 (32.3)            27/41 (39.7)    0.374

P\<0.05. CD47, integrin-associated protein; SD, standard deviation.

###### 

Association between CD47 mRNA expression in peripheral blood and the clinicopathological characteristics of patients with gastric cancer.

                                                     CD47 expression group                   
  -------------------------------------------------- ----------------------- --------------- -------------------------------------------------------
  Total, n                                           86                      88              --
    Age, years, mean ± SD                            59.45±1.32              61.76±1.26      0.207
    Age distribution, n ≥70/\<70 years (% ≥70)       18/68 (20.9)            26/62 (29.5)    0.460
    Gender, male/female (% male)                     59/27 (68.6)            55/33 (62.5)    0.397
  Tumor factors                                                                              
    Tumor size, mm, mean ± SD                        63.29±44.71             82.58±44.45     0.0025^[a](#tfn2-ol-0-0-6257){ref-type="table-fn"}^
    Tumor size distribution, n ≥50/\<50 mm (% ≥50)   38/48 (44.1)            61/27 (69.3)    0.0052^[a](#tfn2-ol-0-0-6257){ref-type="table-fn"}^
    Depth of tumor, n T1-2/T3-4 (% T1-2)             37/49 (43.0)            7/81 (7.9)      \<0.0001^[a](#tfn2-ol-0-0-6257){ref-type="table-fn"}^
    Tumor type, n type 0--1/2-5 (% 0--1)             48/38 (55.8)            23/65 (26.1)    0.0001^[a](#tfn2-ol-0-0-6257){ref-type="table-fn"}^
    Lymphatic invasion, n +/− (% +)                  47/39 (54.6)            63/25 (71.6)    0.00316^[a](#tfn2-ol-0-0-6257){ref-type="table-fn"}^
    Vascular invasion, n +/− (% +)                   20/66 (23.2)            63/25 (71.6)    0.278
  Metastatic factors                                                                         
    Lymph node metastasis, n +/− (% +)               45/41 (52.3)            71/17 (80.6)    0.0002^[a](#tfn2-ol-0-0-6257){ref-type="table-fn"}^
    Liver metastasis, n +/− (% +)                    1/85 (1.1)              3/85 (3.4)      0.324
    Peritoneal (micro) metastasis, n +/− (% +)       11/75 (14.7)            20/68 (22.7)    0.0868
    Peritoneal (macro) metastasis, n +/− (% +)       7/79 (8.1)              11/77 (12.5)    0.340
    Distant metastasis, n +/− (% +)                  2/84 (2.3)              1/87 (1.1)      0.527
  Clinical stage, n I/II--IV (% I)                   45/41 (52.1)              9/79 (10.2)   \<0.0001^[a](#tfn2-ol-0-0-6257){ref-type="table-fn"}^

P\<0.05. CD47, integrin-associated protein; SD, standard deviation.

###### 

Association between CD47 mRNA expression in bone marrow and the clinicopathological characteristics of patients with gastric cancer.

                                                     CD47 expression group                  
  -------------------------------------------------- ----------------------- -------------- -----------------------------------------------------
  Total, n                                           97                      98             --
    Age, years, mean ± SD                            61.2±1.21               62.5±1.21      0.445
    Age distribution, n ≥70/\<70 years (% ≥70)                                              
    Gender, male/female (% male)                     59/38 (60.8)            73/25 (74.5)   0.0408^[a](#tfn3-ol-0-0-6257){ref-type="table-fn"}^
  Tumor factors                                                                             
    Tumor size, mm, mean ± SD                        77.23±48.11             65.87±47.63    0.101
    Tumor size distribution, n ≥50/\<50 mm (% ≥50)   60/37 (61.9)            53/45 (54.1)   0.31
    Depth of tumor, n T1-2/T3-4 (% T1-2)             28/69 (28.7)            46/52 (47.4)   0.0076^[a](#tfn3-ol-0-0-6257){ref-type="table-fn"}^
    Tumor type, n type 0--1/2-5 (% 0--1)             60/37 (61.9)            49/49 (50.0)   0.220
    Lymphatic invasion, n +/− (% +)                  63/34 (65.2)            44/54 (45.2)   0.0071^[a](#tfn3-ol-0-0-6257){ref-type="table-fn"}^
    Vascular invasion, n +/− (% +)                   20/77 (20.9)            24/74 (24.7)   0.545
  Metastatic factors                                                                        
    Lymph node metastasis, n +/− (% +)               74/23 (76.4)            53/45 (54.3)   0.0015^[a](#tfn3-ol-0-0-6257){ref-type="table-fn"}^
    Liver metastasis, n +/− (% +)                    1/96 (1.0)              2/96 (2.0)     0.563
    Peritoneal (micro) metastasis, n +/− (% +)       17/80 (17.5)            16/82 (16.5)   0.848
    Peritoneal (macro) metastasis, n +/− (% +)       10/87 (10.3)            5/93 (5.1)     0.169
    Distant metastasis, n +/− (% +)                  0/97 (0.0)              5/93 (5.1)     0.0081^[a](#tfn3-ol-0-0-6257){ref-type="table-fn"}^
  Clinical stage, n I/II--IV (% I)                   14/83 (14.9)            33/65 (34.0)   0.0019^[a](#tfn3-ol-0-0-6257){ref-type="table-fn"}^

P\<0.05. CD47, integrin-associated protein; SD, standard deviation.
